Emerging Alzheimer's disease treatment paradigms: A late‐stage clinical trial review
Abstract INTRODUCTION Without disease‐modifying interventions, Medicare and Medicaid spending on Alzheimer's disease (AD) management is expected to reach 637 billion USD annually by 2050. The recent advent of promising AD therapies after decades of a near‐total failure rate in clinical trials s...
Saved in:
| Main Authors: | Jakub P. Hlávka, Andrew T. Kinoshita, Divya Jeyasingh, Cheng Huang, Leila Mirsafian, Mireille Jacobson |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.70022 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predictors of knowledge level and awareness towards the principles and methodology evaluation of pharmacoeconomics in Saudi Arabia
by: Dhafer Mahdi Alshayban
Published: (2025-12-01) -
In search of Alzheimer’s disease treatment methods: trends of clinical trials
by: G. Pakulaitė, et al.
Published: (2018-03-01) -
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
by: Clifford R. Jack, et al.
Published: (2024-10-01) -
Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials
by: Jeffrey C. Yu, et al.
Published: (2022-01-01) -
Alzheimer's disease drug development pipeline: 2022
by: Jeffrey Cummings, et al.
Published: (2022-01-01)